Cross-specialty trial OS for Graves and thyroid eye disease programs to find patients faster and capture dual-disease evidence.

1. A $101 million launch financing indicates this is no longer a niche science project and creates immediate budget for the stack around trial execution.
2. A therapy aimed at one shared driver across Graves and TED changes the operating model from single-specialty drug development to cross-specialty patient and evidence orchestration.
3. The fact that today's Graves and TED treatments do not cover each other means sponsors still inherit a fragmented referral and endpoint workflow that software can fix.
4. ENDO 2026 data and a stated second-half 2026 first-in-human timeline compress the window for sponsors to stand up patient-finding and site-readiness infrastructure.
5. A low-volume subcutaneous injection and planned autoinjector make outpatient initiation and longitudinal evidence capture more important than infusion-center logistics.

Catalyst. Ethyreal's financing, explicit dual-indication TSHR thesis, near-term ENDO 2026 data, and planned first-in-human start in the second half of 2026 show the category is moving from scientific framing to operational execution.

The startup would sell a software-plus-ops layer to biotech sponsors building Graves and TED programs. It would help sponsors select and activate sites, define referral handoffs between endocrinology and ophthalmology, and run a structured chart-review and pre-screening workflow that surfaces likely eligible patients without waiting for ad hoc physician memory. The product would also standardize baseline imaging, lab, and symptom packet completion so that early trials generate cleaner dual-disease evidence and future launch teams know where patient leakage occurs. Instead of replacing CRO systems, it would sit on top as the disease-specific operating layer for screening velocity, endpoint completeness, and cross-specialty coordination. Over time, the moat becomes a proprietary dataset linking referral sources, baseline presentation patterns, enrollment speed, and downstream response or retention across Graves/TED programs.

What's different. CROs can run generic studies, patient-support hubs typically activate only after approval, and EMR vendors do not own sponsor-side disease activation workflows. This company would win by owning the narrow but high-value layer between two specialties for a new autoimmune drug class: referral mapping, pre-screening logic, baseline packet completion, and endpoint quality. Its defensibility compounds through a sponsor-specific dataset on where Graves/TED programs lose candidates, which site archetypes enroll fastest, and which evidence bundles best predict downstream treatment fit.

Jobs to be done

flowchart LR
  Buyer[Clinical ops lead] --> Pain[Fragmented Graves and TED patient funnel]
  Pain --> Product[Graves and TED activation OS]
  Product --> Outcome[Faster enrollment and cleaner dual-disease evidence]

Executive takeaways

• The opening is real but narrow: Graves/TED programs are moving from science narrative to execution, yet the buyer pool is still a small set of biotech teams rather than a broad software category.
• The operational pain is credible because TED care is explicitly multidisciplinary, baseline eye assessments are structured, and site startup burden is already rising across specialty trials.
• No incumbent owns this wedge by default. CTMS, recruitment networks, and CRO workflows cover adjacent jobs, but none are optimized for endocrine-to-ophthalmology referral orchestration plus dual-disease evidence completeness.
• The idea is probably venture-interesting only if the company proves Graves/TED first and then expands the same cross-specialty activation layer into adjacent autoimmune programs.

Market definition

Sponsor-side workflow software and services for Graves disease and thyroid eye disease asset teams that need to find patients across endocrinology and ophthalmology, standardize baseline packet collection, and track screening and endpoint completeness across 10-40-site early clinical programs. The market is narrower than general CTMS, patient recruitment, or DCT tooling: it is the disease-specific activation layer between specialty referral, pre-screening, and audit-ready evidence capture.

Customer and buyer

The daily user is the clinical operations, medical affairs, or site-enablement team inside a biotech sponsor coordinating endocrinology and ophthalmology sites. The economic buyer is the CMO, COO, or SVP Clinical Development because the problem sits at the intersection of study startup, enrollment risk, and whether early Graves/TED data packages are credible enough for boards, regulators, and future launch planning.

Buying triggers

• Category-defining financings and near-term clinical transitions make workflow spend easier to justify before first patient in. [6][9]
• TED guidance explicitly calls for timely referral and joint endocrinology-ophthalmology management, which turns fragmented specialty handoffs into a concrete operational problem. [2][3][4]
• Sites already report long delays and heavy manual effort in protocol-guided source preparation, so sponsors have a reason to pay for narrower workflow acceleration instead of more generic dashboards. [16][17]
• Registrational and late-stage TED competition raises the value of faster enrollment and cleaner baseline evidence as a differentiator. [5][9][10]

Willingness to pay

Buyers already spend on CTMS, recruitment, and compliance systems, so this does not need a net-new software budget category. The best payment argument is avoiding enrollment delay and incomplete baseline packets, not selling generic AI. Public vendor pages show an established market of quote-based trial-ops software and at least some low-end paid CTMS spend, which supports a credible wedge if it is tied to days-to-screen, packet completeness, and sponsor oversight. [19][21][22][23][24]

Category dynamics

Growth signal No credible published niche CAGR; low-base expansion driven by new GD/TED programs

Validation signals

• Ethyreal launched with $101M and plans first-in-human testing in the second half of 2026, showing real buyer-side urgency in the category.
• Viridian already has a TED BLA under Priority Review, proving the adjacent commercial market is maturing quickly.
• Immunovant publicly sizes a U.S. GD population of roughly 880,000 and a relapsed, non-surgical segment of about 330,000, supporting persistent unmet need.
• Sites report nearly six weeks of delay and more than 21 hours of source-prep work for high-complexity studies, validating the underlying workflow pain.

Regulatory & technical constraints

• Electronic systems used in clinical investigations must produce trustworthy, reliable records and signatures with clear sponsor and investigator controls.
• TED workups require consistent ophthalmic assessment, severity scoring, and imaging choices when clinically indicated, so baseline packet logic cannot be ad hoc.
• Graves and TED patient heterogeneity, smoking status, thyroid control, and disease activity complicate pre-screening logic and cohort comparability.

Competition comes from four directions: horizontal CTMS/eTMF systems, recruitment and access networks, site-focused trial operations tools, and the entrenched substitute of CRO plus coordinator spreadsheets. The strategic gap is not general clinical trial software; it is a narrowly opinionated layer for endocrine-to-ophthalmology referral logic, baseline packet standardization, and site-by-site dual-disease evidence quality.

Why incumbents do not win by default

• CTMS and eTMF suites. They own broad study management, monitoring, and documentation workflows, but they start from generic study objects rather than Graves/TED-specific referral and baseline packet logic.
• Recruitment and access networks. Networks such as Circuit attack top-of-funnel participation and site support, but they do not win by default on sponsor-specific cross-specialty packet completeness and endpoint readiness.
• Site-focused trial platforms. Site tools can help recruit participants and collaborate with sponsors, yet their center of gravity is site execution rather than sponsor-owned disease workflow across multiple external centers.
• Manual CRO and coordinator workflows. This remains the default substitute because it is flexible and familiar, but the same literature shows it preserves hidden startup delays, cross-document inconsistency, and high preparation burden.

Graves TED Trial OS is a sponsor-facing activation layer for biotech teams running Graves disease and thyroid eye disease programs across endocrinology and ophthalmology sites. The plan is to start with U.S. Series A-C sponsors entering Phase I or Phase II with 10-40 North American sites, where the immediate problem is not generic CTMS administration but referral leakage, inconsistent baseline packets, and slow first-patient screening across two specialties. Research supports a real operational trigger because TED care is explicitly multidisciplinary, site startup burden is already high, and category financing and pipeline progress make pre-FPI execution spend easier to justify. The wedge is narrow by design: standardize endocrine-to- ophthalmology referral paths, pre-screen likely candidates, and track baseline imaging, labs, and endpoint completeness from referral through first dose. This company should not try to replace CROs, EDC, or broad CTMS suites early; it should win as the thin disease-specific layer those systems do not provide. The main attraction is faster enrollment and cleaner dual-disease evidence for sponsors whose next financing, board update, or partnering narrative depends on early trial momentum. The main constraint is market size: the researched TAM is only about $6.0M in the current niche, so the venture case depends on proving Graves/TED first and then reusing the same workflow ontology in adjacent autoimmune programs. The biggest missing fact is direct site-level evidence on referral leakage and packet failure rates in active Graves/TED programs, so the first 90 days must validate that this pain is large enough to support repeatable $250k-$400k annual contracts.

Problem

• Sponsors running Graves and TED studies inherit fragmented endocrinology and ophthalmology workflows, so the right patients are identified late, handed off inconsistently, or lost before full eligibility review.
• Baseline imaging, lab, symptom, and severity-assessment packets are assembled manually across sites, which slows enrollment and weakens the credibility of early dual-disease evidence.

Solution

• Provide a Graves/TED activation OS that maps referral paths, manages pre-screening queues, standardizes baseline packet requirements, and gives sponsors site-level visibility into screening velocity and evidence completeness.
• Layer on top of CRO, CTMS, imaging, and lab workflows rather than replacing them, so sponsors can improve first-patient speed and packet quality without a rip-and-replace of core trial systems.

Why we win

• Horizontal CTMS, recruitment vendors, and CRO services cover adjacent work but do not own the Graves/TED-specific referral logic and baseline packet model across endocrinology and ophthalmology.
• Each deployment builds a proprietary dataset on referral sources, screen-fail reasons, missing packet elements, and site archetypes that can improve forecasting, onboarding, and expansion into adjacent autoimmune programs.

Milestones

flowchart LR
  Wedge[Graves TED activation wedge] --> MVP[Referral and packet workflow MVP]
  MVP --> Proof[Faster screening and cleaner evidence]
  Proof --> Expansion[Adjacent autoimmune activation platform]

Founding team

Experiment roadmap

Risk assessment

What must be true

• At least 40% of referred candidates in pilot programs must currently fail to reach full eligibility review because of handoff or packet-completion gaps.
• At least 3 venture-backed Graves/TED sponsors per year must have both budget authority and timeline urgency to buy before first-patient-in.
• The product must reduce days to first screened patient by at least 20% versus the sponsor's planned workflow.
• Sites must adopt the workflow with limited additional coordinator burden and without requiring the startup to become a services-heavy CRO substitute.
• The same workflow ontology must transfer into at least one adjacent autoimmune category within 24 months to expand beyond the initial $6.0M niche.

Open diligence questions

• Who actually owns budget for cross-specialty activation before first patient in: clinical ops, medical affairs, or the CMO?
• What portion of patient leakage in current programs comes from referral handoff versus strict eligibility failure?
• Which packet elements most often block sponsor-ready screening review across Graves/TED sites?
• Will buyers accept a thin export-first layer, or demand deeper CTMS and document-system integration before pilot approval?
• How many credible beachhead programs will still exist after current TED leaders commercialize or late-stage programs slip?

Model sanity

• Revenue engine. Base-case revenue comes almost entirely from converting three niche asset programs into roughly $0.4M production contracts rather than from broad logo volume.
• Must go right. The first two pilots must convert on schedule because each lost program removes about one-third of the year-3 revenue base.
• Model breaks if. If implementations stay services-heavy and mature gross margin sticks near 65%, the $2.4M round no longer preserves a clean seed-raise buffer.
• Next-round proof. A credible seed story requires three active programs, one partner-sourced win, and evidence that the workflow ontology extends into one adjacent autoimmune category.

Scenarios

Sensitivity

flowchart LR
  Leads[ICP sponsors] --> Pilots[Paid pilots]
  Pilots --> Production[Annual programs]
  Production --> Revenue[Program revenue]
  Revenue --> GrossProfit[Gross profit]
  GrossProfit --> Cash[Cash runway]

Flags: The researched beachhead is small enough that the base case effectively assumes near-perfect execution on the first three meaningful program opportunities. · The company is still EBITDA negative in Y3, so this round buys proof and seed readiness rather than self-sufficiency. · Revenue per FTE remains below normal SaaS benchmarks because packet setup, compliance, and implementation work still consume meaningful labor. · Unit economics look attractive only if gross margin truly clears 70%; a CRO-like services mix would compress LTV/CAC quickly.

• Clinical timing risk. If first-wave Graves and TED assets slip or fail, sponsor budgets for a category-specific activation layer could evaporate before the company scales. Mitigation: Start with protocol-agnostic workflow modules that also support natural-history studies, medical-affairs evidence generation, and later commercial readiness across adjacent autoimmune programs.
• Site workflow resistance. Endocrinology and ophthalmology sites may resist adding another sponsor workflow if it feels like extra coordinator work without clear patient benefit. Mitigation: Launch with lightweight coordinator tools, services-assisted setup, and dashboards that directly reduce missing packets, duplicate outreach, and screening confusion.
• CRO bundling pressure. Large CROs could try to absorb the wedge into broader trial-ops contracts once the pain is visible. Mitigation: Integrate with CRO systems rather than replace them and build a differentiated Graves/TED dataset around referral patterns, endpoint completeness, and site archetype performance.